The research team identified SMARCD1, a core subunit of the SWI/SNF complex, as a tumor suppressor whose activity is progressively extinguished in clear cell renal cell carcinoma. The silencing mechanism is epigenetic rather than genetic: the promoter region of the SMARCD1 gene becomes heavily methylated through the action of DNMT3B, a DNA methyltransferase enzyme that adds methyl groups to cytosine bases in DNA. Promoter hypermethylation of this kind acts like a molecular lock on gene expression, preventing the transcriptional machinery from reading the gene. As methylation accumulates, SMARCD1 protein levels fall, and with them the ability of the SWI/SNF complex to properly organize chromatin at its target sites.

What makes this finding compelling is the chain of events that follows. Using a combination of molecular biology approaches, the researchers showed that when SMARCD1 is lost, an RNA helicase called DDX3X gains the ability to bind to the promoter of a gene called MAFF. MAFF encodes a small transcription factor of the bZIP family, and its upregulation sets off a cascade with profound consequences for cellular metabolism. The team demonstrated that MAFF, once overproduced, promotes the ubiquitin-mediated degradation of MFN1, mitofusin 1, a GTPase embedded in the outer mitochondrial membrane that is essential for mitochondrial fusion.

Mitochondrial fusion is not a cosmetic process. Healthy cells continuously fuse and re-fuse their mitochondria, mixing the contents of these organelles and maintaining a functional network of tubules that supports efficient energy production, calcium handling, and quality control. When MFN1 is degraded, fusion collapses, mitochondria fragment, and the cell’s metabolic architecture is fundamentally altered. In the SMARCD1-deficient cancer cells studied here, the authors found that this fragmentation reprograms metabolism toward oxidative phosphorylation, the oxygen-dependent mode of ATP generation that many tumors exploit to fuel growth and survival under stress. The disrupted fusion state also enhanced the metastatic potential of the cancer cells, linking a chromatin defect all the way to the clinical behavior of the disease.

This SMARCD1–MAFF–MFN1 axis therefore represents a direct mechanistic bridge between two fields that have largely developed in parallel: chromatin remodeling biology and mitochondrial dynamics. SWI/SNF complexes are mutated or silenced in roughly one in five of all human cancers, and components such as SMARCB1, SMARCA4 and ARID1A have been extensively characterized as tumor suppressors. Mitochondrial reprogramming, meanwhile, is a recognized hallmark of cancer, with shifts in oxidative phosphorylation and mitochondrial morphology increasingly appreciated as drivers of progression and treatment resistance. The new work shows that in ccRCC these two hallmarks are not merely correlated but causally connected through a defined signaling pathway, offering a template for understanding how epigenetic lesions might sculpt metabolism in other tumor types as well.

The therapeutic implications may prove to be the most consequential part of the story. Because the pathway ends in the loss of MFN1, the researchers asked whether restoring mitochondrial fusion pharmacologically could reverse the malignant state. Their search led to leflunomide, an immunosuppressive drug approved by the US Food and Drug Administration that is already used to treat rheumatoid arthritis and psoriatic arthritis. Leflunomide is best known as an inhibitor of dihydroorotate dehydrogenase, an enzyme in the pyrimidine synthesis pathway, but in this context the team found that the drug acts to restore MFN1 levels and mitochondrial function in SMARCD1-deficient cells.

In multiple preclinical models, the authors reported that leflunomide reversed the mitochondrial dysfunction caused by SMARCD1 loss and suppressed tumor progression. The effect extended beyond the drug alone: in patient-derived xenografts, models in which fragments of human tumors are grown in mice and retain much of the molecular character of the original cancers, leflunomide potentiated the efficacy of both tyrosine kinase inhibitors and immune checkpoint blockade. This combination potential matters enormously for kidney cancer, because advanced ccRCC is currently managed with precisely these drug classes. Tyrosine kinase inhibitors targeting VEGF signaling and immune checkpoint inhibitors targeting PD-1 or PD-L1 form the backbone of first-line therapy, yet resistance develops in many patients, and additional rational combinations are urgently needed.

The prospect of repurposing a decades-old, well-characterized drug is particularly attractive from a drug-development standpoint. Leflunomide has an established human safety profile, known pharmacokinetics, and generic availability, all of which could shorten the path from laboratory finding to clinical testing. The study’s identification of SMARCD1 promoter methylation as the initiating lesion also suggests a potential biomarker strategy: patients whose tumors show SMARCD1 silencing might be selected for leflunomide-based treatment, an approach consistent with the broader movement toward molecularly stratified oncology. The authors note that their findings highlight leflunomide repurposing as a clinically actionable strategy specifically in SMARCD1-deficient ccRCC, framing the drug as part of a precision-medicine approach rather than a universal kidney cancer therapy.

Scientifically, the study adds ccRCC to a growing list of cancers in which SWI/SNF subunits act as linchpins connecting nuclear architecture to cellular physiology. It also underscores the emerging view that mitochondria are active participants in the epigenetic state of the cell, not passive power supplies. The finding that a chromatin-remodeling defect ultimately funnels through a transcription factor and a mitochondrial fusion protein to reshape oxidative phosphorylation illustrates how tumor suppressor loss can produce metabolic phenotypes that are themselves druggable. If the pathway operates as described in patients, measuring MAFF levels, MFN1 abundance, or mitochondrial morphology in tumor biopsies could offer readouts of pathway activity and treatment response.

Considerable work remains before leflunomide can be recommended for kidney cancer patients, including formal clinical trials to establish efficacy, dosing, and safety in the oncology setting, and to determine which molecular subgroups benefit most. The preclinical evidence, however, spans cell lines, animal models, and patient-derived xenografts, and the drug’s approval status gives the finding a rare immediacy. For a disease in which SWI/SNF dysfunction has been observed for years without a clear mechanistic handle, the demonstration that SMARCD1 loss drives progression through mitochondrial reprogramming, and that this process can be pharmacologically reversed, marks a significant step forward in understanding and potentially treating one of the most challenging urological malignancies.

Subject of Research: SMARCD1 deficiency-driven mitochondrial reprogramming in clear cell renal cell carcinoma and its therapeutic reversal with leflunomide

Article Title: SWI/SNF subunit SMARCD1 deficiency promotes clear cell renal cell carcinoma progression via mitochondrial reprogramming

Article References: Un, W., Hao, C., Wang, Z., Sun, D., Song, K., Deng, D., Li, L., Hu, Z., Zhao, Q., Wang, Q. K., Yao, Y., & Zeng, X. (2026). SWI/SNF subunit SMARCD1 deficiency promotes clear cell renal cell carcinoma progression via mitochondrial reprogramming. Nature Communications. https://doi.org/10.1038/s41467-026-78285-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78285-3

Keywords: clear cell renal cell carcinoma, SMARCD1, SWI/SNF complex, mitochondrial reprogramming, MFN1, MAFF, DNMT3B, leflunomide, drug repurposing, oxidative phosphorylation, epigenetics, patient-derived xenografts